Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Human Leukocyte Antigen (HLA)-presented peptide complex is a specialized molecular structure responsible for presenting antigenic peptides to T lymphocytes, playing a critical role in immune recognition and response[1][3]. This complex consists of an HLA molecule (either class I or class II) bound to a peptide fragment derived from proteins processed within the cell. HLA class I molecules, found on virtually all nucleated cells, consist of a heavy chain (44-47 kD) non-covalently linked to a β2-microglobulin light chain (12 kD)[1]. The heavy chain contains three domains: a cytoplasmic region with a peptide-binding groove formed by α1 and α2 domains, a transmembrane region anchoring the molecule to the cell membrane, and a conserved α3 immunoglobulin-like domain that binds CD8[1]. The peptide-binding groove of HLA class I typically accommodates peptides of 8-10 amino acids in length, though longer peptides can bind with their central portions bulging outward[1]. This groove contains distinct pockets (A, B, C, D, E, and F) that vary in chemical properties between different HLA alleles, creating preferred sequence "motifs" with anchor residues that fit into these pockets[1]. The antigen processing pathway for HLA class I involves proteasomal degradation of endogenous proteins, peptide transport into the endoplasmic reticulum via TAP (Transporter Associated with Antigen Processing), and loading onto newly synthesized HLA molecules with assistance from chaperone proteins including calnexin, calreticulin, ERp57, and tapasin[5][6]. The fully assembled HLA-peptide complex is then transported to the cell surface where it can be recognized by CD8+ T cells[6]. HLA class II molecules follow a different pathway, synthesized in the endoplasmic reticulum with an invariant chain occupying the peptide-binding groove[6]. This complex is directed to endosomal compartments where the invariant chain is degraded, leaving a CLIP (Class II-associated Invariant chain Peptide) fragment that is exchanged for antigenic peptides with help from HLA-DM molecules[4][6]. The resulting HLA class II-peptide complex is presented on the cell surface to CD4+ T cells[6]. Non-classical HLA molecules like HLA-F have more specialized functions, including stabilizing free forms of HLA class I molecules and interacting with receptors on natural killer cells[7][8]. The HLA-peptide complex system is highly polymorphic, allowing for presentation of diverse peptide repertoires and contributing to individual variations in immune responses to pathogens and susceptibility to autoimmune diseases[1][3].
Peptide binding and presentation to T cells Interaction with T cell receptors Engagement with NK cell receptors
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human Leukocyte Antigen-presented peptide complex (HLA-peptide complex).